Justin Greiwe is a Rheumatology/Immunology physician. OpenAlex indexes 50 publications with 1,017 citations (h-index 16).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4665 E Galbraith Rd Fl 2
Cincinnati, OH 452362783
Telephone
513-931-0775Provider last certified this registry record 26 Jul 2022.
Industry payments
53 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year2025126 payments$116,687openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year202558 payments$78,779openpaymentsdata.cms.gov ↗
- Genentech USA, Inc.Program year202528 payments$22,578openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
85.4%Corticosteroid35.6%Fluticasone Propionate22%Trelegy Ellipta22%Breo Ellipta21%Arnuity Ellipta16%Symbicort13%Qvar Redihaler7%Part D<11 patientsHistamine-1 Receptor Antagonist25.7%Azelastine Hcl89%Azelastine-Fluticasone11%Part D<11 patients+ 4 more classes in this area
Dermatology
6.9%Interleukin-4 Receptor alpha Antagonist6.9%Dupixent Pen68%Dupixent Syringe32%Part D<11 patientsMetabolism & gastrointestinal
4.7%Corticosteroid4.7%Prednisone100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Tapinarof Cream 1% Once Daily: Consistent Efficacy Across All Body Regions, Including Head And Neck, In Adults And Children Down To 2 Years Of Age With Atopic Dermatitis
Journal of Allergy and Clinical Immunology
2025 - Preparing Patients for Oral Immunotherapy (PPOINT): International Delphi consensus for procedural preparation and consent
Journal of Allergy and Clinical Immunology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”